Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Ofloxacin

&times

Overview

What is Ofloxacin ophthalmic?

Ofloxacin Ophthalmic Solution

USP

,

0.3%

Chemical Name:

Contains:

Preservative:

Inactives:

Ofloxacinophthalmic solution, USP is unbuffered and formulated with a pH of 6.4 (range - 6.0 to 6.8). It has an osmolality of 300 mOsm/kg. Ofloxacin is a fluorinated 4-quinolone which differs from other fluorinated 4-quinolones in that there is a six member (pyridobenzoxazine) ring from positions 1 to 8 of the basic ring structure.



What does Ofloxacin ophthalmic look like?



What are the available doses of Ofloxacin ophthalmic?

Sorry No records found.

What should I talk to my health care provider before I take Ofloxacin ophthalmic?

Sorry No records found

How should I use Ofloxacin ophthalmic?

Ofloxacin ophthalmic solution, USP is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:

      * Efficacy for this organism was studied in fewer than 10 infections

The recommended dosage regimen for the treatment of is:

The recommended dosage regimen for the treatment of is:


What interacts with Ofloxacin ophthalmic?

Sorry No Records found


What are the warnings of Ofloxacin ophthalmic?

Sorry No Records found


What are the precautions of Ofloxacin ophthalmic?

Sorry No Records found


What are the side effects of Ofloxacin ophthalmic?

Sorry No records found


What should I look out for while using Ofloxacin ophthalmic?

Ofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication.

NOT FOR INJECTION.

Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolones, including ofloxacin. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching. A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin. If an allergic reaction to ofloxacin occurs, discontinue the drug. Serious acute hypersensitivity reactions may require immediate emergency treatment. Oxygen and airway management, including intubation should be administered as clinically indicated.


What might happen if I take too much Ofloxacin ophthalmic?

Sorry No Records found


How should I store and handle Ofloxacin ophthalmic?

Store Temozolomide Capsules at 25°C (77°F); excursions permitted to 15°–30°C (59°–86°F) [see USP Controlled Room Temperature].Ofloxacin ophthalmic solution USP, 0.3% is supplied sterile in opaque white LDPE plastic bottles and natural dropper tips with tan polypropylene caps as follows:       5mL in 10mL bottle - NDC 59390-140-05Note: Rx only Revised March 2013                                                    Aquebogue N.Y. 11931, U.S.A. Ofloxacin ophthalmic solution USP, 0.3% is supplied sterile in opaque white LDPE plastic bottles and natural dropper tips with tan polypropylene caps as follows:       5mL in 10mL bottle - NDC 59390-140-05Note: Rx only Revised March 2013                                                    Aquebogue N.Y. 11931, U.S.A. Ofloxacin ophthalmic solution USP, 0.3% is supplied sterile in opaque white LDPE plastic bottles and natural dropper tips with tan polypropylene caps as follows:       5mL in 10mL bottle - NDC 59390-140-05Note: Rx only Revised March 2013                                                    Aquebogue N.Y. 11931, U.S.A. Ofloxacin ophthalmic solution USP, 0.3% is supplied sterile in opaque white LDPE plastic bottles and natural dropper tips with tan polypropylene caps as follows:       5mL in 10mL bottle - NDC 59390-140-05Note: Rx only Revised March 2013                                                    Aquebogue N.Y. 11931, U.S.A. Ofloxacin ophthalmic solution USP, 0.3% is supplied sterile in opaque white LDPE plastic bottles and natural dropper tips with tan polypropylene caps as follows:       5mL in 10mL bottle - NDC 59390-140-05Note: Rx only Revised March 2013                                                    Aquebogue N.Y. 11931, U.S.A. Ofloxacin ophthalmic solution USP, 0.3% is supplied sterile in opaque white LDPE plastic bottles and natural dropper tips with tan polypropylene caps as follows:       5mL in 10mL bottle - NDC 59390-140-05Note: Rx only Revised March 2013                                                    Aquebogue N.Y. 11931, U.S.A. Ofloxacin ophthalmic solution USP, 0.3% is supplied sterile in opaque white LDPE plastic bottles and natural dropper tips with tan polypropylene caps as follows:       5mL in 10mL bottle - NDC 59390-140-05Note: Rx only Revised March 2013                                                    Aquebogue N.Y. 11931, U.S.A.


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Serum, urine and tear concentrations of ofloxacin were measured in 30 healthy women at various time points during a ten-day course of treatment with ofloxacin ophthalmic solution. The mean serum ofloxacin concentration ranged from 0.4 ng/mL to 1.9 ng/mL. Maximum ofloxacin concentration increased from 1.1 ng/mL on day one to 1.9 ng/mL on day 11 after QID dosing for 10 1/2 days. Maximum serum ofloxacin concentrations after ten days of topical ophthalmic dosing were more than 1000 times lower than those reported after standard oral doses of ofloxacin.

Tear ofloxacin concentrations ranged from 5.7 to 31 ug/g during the 40 minute period following the last dose on day 11. Mean tear concentration measured four hours after topical ophthalmic dosing was 9.2 ug/g.

Corneal tissue concentrations of 4.4 ug/mL were observed four hours after beginning topical ocular application of two drops of ofloxacin ophthalmic solution every 30 minutes. Ofloxacin was excreted in the urine primarily unmodified.

Non-Clinical Toxicology
Ofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication.

NOT FOR INJECTION.

Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolones, including ofloxacin. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching. A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin. If an allergic reaction to ofloxacin occurs, discontinue the drug. Serious acute hypersensitivity reactions may require immediate emergency treatment. Oxygen and airway management, including intubation should be administered as clinically indicated.

Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.

As with other anti-infectives, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. Ofloxacin should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity reaction.

The systemic administration of quinolones, including ofloxacin, has led to lesions or erosions of the cartilage in weight-bearing joints and other signs of arthropathy in immature animals of various species. Ofloxacin, administered systemically at 10 mg/kg/day in young dogs (equivalent to 110 times the maximum recommended daily adult ophthalmic dose) has been associated with these types of effects.

Ophthalmic Use:

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).